Cargando…
A simple immunohistochemical bio-profile incorporating Bcl2 curbs those cases of invasive breast carcinoma for which an Oncotype Dx characterization is needed
AIM: Our goal has been to evaluate the importance that the incorporation of Bcl2 in the ER/PGR/Her2/Ki67 bio-profile can have as predictor of the Oncotype Dx categories. MATERIAL AND METHODS: 156 consecutive cases of HR+/Her2- pN0/1 primary breast carcinoma were sent to the Oncotype Dx test. Immunoh...
Autores principales: | , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Public Library of Science
2019
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6546245/ https://www.ncbi.nlm.nih.gov/pubmed/31158261 http://dx.doi.org/10.1371/journal.pone.0217937 |
_version_ | 1783423515901296640 |
---|---|
author | Ceccarelli, Claudio De Leo, Antonio Chieco, Pasquale Zamagni, Claudio Zamagni, Alice Rubino, Daniela Taffurelli, Mario Santini, Donatella |
author_facet | Ceccarelli, Claudio De Leo, Antonio Chieco, Pasquale Zamagni, Claudio Zamagni, Alice Rubino, Daniela Taffurelli, Mario Santini, Donatella |
author_sort | Ceccarelli, Claudio |
collection | PubMed |
description | AIM: Our goal has been to evaluate the importance that the incorporation of Bcl2 in the ER/PGR/Her2/Ki67 bio-profile can have as predictor of the Oncotype Dx categories. MATERIAL AND METHODS: 156 consecutive cases of HR+/Her2- pN0/1 primary breast carcinoma were sent to the Oncotype Dx test. Immunohistochemical determination of Bcl2/ER/PGR/Ki67/Her2 expression was evaluated for each case. After the selection of the appropriate cut-off values for PGR and Ki67, explorative as well as confirmative statistical analyses were performed to build and validate predictive risk-of-recurrence immunohistochemical only bio-profiles. RESULTS: The predictive capacity of these immunohistochemical profiles was compared with both traditional and TAILORx Oncotype Dx risk class classification. This comparison showed that immunohistochemical bio-profiles select those cases not associated with high risk-of-recurrence of disease (luminal-A/B and luminal A/B Bcl2) and those that are instead at high risk and therefore worthy of chemotherapy (luminal-B ki67 and luminal-B Bcl2/Ki67), strongly suggesting to only submit PGR-positive/Bcl2-Ki67 altered cases to Oncotype Dx, thus reducing the number of cases to be tested. CONCLUSIONS: Our results indicate that the addition of Bcl2 to an immunohistochemical bio-profile definitely improves its predictive capacity to correctly select which cases to send to the Oncotype Dx test. We have also suggested that institutions with a significant number of breast carcinomas sent to the Oncotype Dx test can use these latter to derive their own PGR and Ki67 cut-off values, overcoming the drawbacks of sharing common inter-laboratory values. Validation of these bio-profiles as predictors of the Oncotype Dx categories is ongoing in a prospective series of new cases. |
format | Online Article Text |
id | pubmed-6546245 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2019 |
publisher | Public Library of Science |
record_format | MEDLINE/PubMed |
spelling | pubmed-65462452019-06-17 A simple immunohistochemical bio-profile incorporating Bcl2 curbs those cases of invasive breast carcinoma for which an Oncotype Dx characterization is needed Ceccarelli, Claudio De Leo, Antonio Chieco, Pasquale Zamagni, Claudio Zamagni, Alice Rubino, Daniela Taffurelli, Mario Santini, Donatella PLoS One Research Article AIM: Our goal has been to evaluate the importance that the incorporation of Bcl2 in the ER/PGR/Her2/Ki67 bio-profile can have as predictor of the Oncotype Dx categories. MATERIAL AND METHODS: 156 consecutive cases of HR+/Her2- pN0/1 primary breast carcinoma were sent to the Oncotype Dx test. Immunohistochemical determination of Bcl2/ER/PGR/Ki67/Her2 expression was evaluated for each case. After the selection of the appropriate cut-off values for PGR and Ki67, explorative as well as confirmative statistical analyses were performed to build and validate predictive risk-of-recurrence immunohistochemical only bio-profiles. RESULTS: The predictive capacity of these immunohistochemical profiles was compared with both traditional and TAILORx Oncotype Dx risk class classification. This comparison showed that immunohistochemical bio-profiles select those cases not associated with high risk-of-recurrence of disease (luminal-A/B and luminal A/B Bcl2) and those that are instead at high risk and therefore worthy of chemotherapy (luminal-B ki67 and luminal-B Bcl2/Ki67), strongly suggesting to only submit PGR-positive/Bcl2-Ki67 altered cases to Oncotype Dx, thus reducing the number of cases to be tested. CONCLUSIONS: Our results indicate that the addition of Bcl2 to an immunohistochemical bio-profile definitely improves its predictive capacity to correctly select which cases to send to the Oncotype Dx test. We have also suggested that institutions with a significant number of breast carcinomas sent to the Oncotype Dx test can use these latter to derive their own PGR and Ki67 cut-off values, overcoming the drawbacks of sharing common inter-laboratory values. Validation of these bio-profiles as predictors of the Oncotype Dx categories is ongoing in a prospective series of new cases. Public Library of Science 2019-06-03 /pmc/articles/PMC6546245/ /pubmed/31158261 http://dx.doi.org/10.1371/journal.pone.0217937 Text en © 2019 Ceccarelli et al http://creativecommons.org/licenses/by/4.0/ This is an open access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/4.0/) , which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited. |
spellingShingle | Research Article Ceccarelli, Claudio De Leo, Antonio Chieco, Pasquale Zamagni, Claudio Zamagni, Alice Rubino, Daniela Taffurelli, Mario Santini, Donatella A simple immunohistochemical bio-profile incorporating Bcl2 curbs those cases of invasive breast carcinoma for which an Oncotype Dx characterization is needed |
title | A simple immunohistochemical bio-profile incorporating Bcl2 curbs those cases of invasive breast carcinoma for which an Oncotype Dx characterization is needed |
title_full | A simple immunohistochemical bio-profile incorporating Bcl2 curbs those cases of invasive breast carcinoma for which an Oncotype Dx characterization is needed |
title_fullStr | A simple immunohistochemical bio-profile incorporating Bcl2 curbs those cases of invasive breast carcinoma for which an Oncotype Dx characterization is needed |
title_full_unstemmed | A simple immunohistochemical bio-profile incorporating Bcl2 curbs those cases of invasive breast carcinoma for which an Oncotype Dx characterization is needed |
title_short | A simple immunohistochemical bio-profile incorporating Bcl2 curbs those cases of invasive breast carcinoma for which an Oncotype Dx characterization is needed |
title_sort | simple immunohistochemical bio-profile incorporating bcl2 curbs those cases of invasive breast carcinoma for which an oncotype dx characterization is needed |
topic | Research Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6546245/ https://www.ncbi.nlm.nih.gov/pubmed/31158261 http://dx.doi.org/10.1371/journal.pone.0217937 |
work_keys_str_mv | AT ceccarelliclaudio asimpleimmunohistochemicalbioprofileincorporatingbcl2curbsthosecasesofinvasivebreastcarcinomaforwhichanoncotypedxcharacterizationisneeded AT deleoantonio asimpleimmunohistochemicalbioprofileincorporatingbcl2curbsthosecasesofinvasivebreastcarcinomaforwhichanoncotypedxcharacterizationisneeded AT chiecopasquale asimpleimmunohistochemicalbioprofileincorporatingbcl2curbsthosecasesofinvasivebreastcarcinomaforwhichanoncotypedxcharacterizationisneeded AT zamagniclaudio asimpleimmunohistochemicalbioprofileincorporatingbcl2curbsthosecasesofinvasivebreastcarcinomaforwhichanoncotypedxcharacterizationisneeded AT zamagnialice asimpleimmunohistochemicalbioprofileincorporatingbcl2curbsthosecasesofinvasivebreastcarcinomaforwhichanoncotypedxcharacterizationisneeded AT rubinodaniela asimpleimmunohistochemicalbioprofileincorporatingbcl2curbsthosecasesofinvasivebreastcarcinomaforwhichanoncotypedxcharacterizationisneeded AT taffurellimario asimpleimmunohistochemicalbioprofileincorporatingbcl2curbsthosecasesofinvasivebreastcarcinomaforwhichanoncotypedxcharacterizationisneeded AT santinidonatella asimpleimmunohistochemicalbioprofileincorporatingbcl2curbsthosecasesofinvasivebreastcarcinomaforwhichanoncotypedxcharacterizationisneeded AT ceccarelliclaudio simpleimmunohistochemicalbioprofileincorporatingbcl2curbsthosecasesofinvasivebreastcarcinomaforwhichanoncotypedxcharacterizationisneeded AT deleoantonio simpleimmunohistochemicalbioprofileincorporatingbcl2curbsthosecasesofinvasivebreastcarcinomaforwhichanoncotypedxcharacterizationisneeded AT chiecopasquale simpleimmunohistochemicalbioprofileincorporatingbcl2curbsthosecasesofinvasivebreastcarcinomaforwhichanoncotypedxcharacterizationisneeded AT zamagniclaudio simpleimmunohistochemicalbioprofileincorporatingbcl2curbsthosecasesofinvasivebreastcarcinomaforwhichanoncotypedxcharacterizationisneeded AT zamagnialice simpleimmunohistochemicalbioprofileincorporatingbcl2curbsthosecasesofinvasivebreastcarcinomaforwhichanoncotypedxcharacterizationisneeded AT rubinodaniela simpleimmunohistochemicalbioprofileincorporatingbcl2curbsthosecasesofinvasivebreastcarcinomaforwhichanoncotypedxcharacterizationisneeded AT taffurellimario simpleimmunohistochemicalbioprofileincorporatingbcl2curbsthosecasesofinvasivebreastcarcinomaforwhichanoncotypedxcharacterizationisneeded AT santinidonatella simpleimmunohistochemicalbioprofileincorporatingbcl2curbsthosecasesofinvasivebreastcarcinomaforwhichanoncotypedxcharacterizationisneeded |